Clinical Trials Logo

Neurological Diseases clinical trials

View clinical trials related to Neurological Diseases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04995848 Recruiting - Cancer Clinical Trials

Telepalliation - Digital Platform for Patients in Palliation and Their Relatives

Start date: May 26, 2021
Phase: N/A
Study type: Interventional

This project has focus on patients in palliation testing a digital platform TelePal.dk.

NCT ID: NCT04846764 Recruiting - Clinical trials for Central Nervous System

Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)

ANéRAVIMM
Start date: April 28, 2021
Phase: N/A
Study type: Interventional

Learning a person's name, new words, or simply remembering where the last conversation with a friend was held are examples of associative memory, frequently disturbed in brain pathologies, but also by aging. Although typically dependent on the hippocampus in the brain, a series of findings suggest that associative memory may persist, under certain circumstances, despite hippocampal damage. The ANéRAVIMM project aims to reveal this learning system, its cognitive and cerebral bases, and to evaluate its potential in patients with memory disorders.

NCT ID: NCT02018406 Recruiting - Cerebral Palsy Clinical Trials

Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

Start date: July 5, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of our study is to determine the safety and efficacy of the combination of erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF) in patients with neurological diseases. To be specific, our clinical study is expected that the combination injection of EPO and G-CSF shows neurotrophic and neuroprotective effects by facilitating endogenous repair process in patients with neurological diseases including stroke, cerebral palsy, or atypical parkinsonism. Therefore, we will apply our original treatment technique in patients with neurological diseases, which is expected to overcome current ethical and technical limitations of less evidenced functional recovery, hematological changes, and side effects. Eventually, We will establish a comprehensive clinical background about neurotrophic and neuroprotective effects of this hematopoietic growth factors therapy.